Demographic and baseline ocular characteristics of Japanese participants with PCV
| Characteristic | Brolucizumab 6 mg (n=39) | Aflibercept 2 mg (n=30) |
| BCVA, letters, mean (SD) | 62.4 (13.9) | 62.4 (10.8) |
| CST, µm, mean (SD) | 392.8 (96.1) | 444.8 (129.0) |
| Presence of IRF and/or SRF, n (%) | 37 (94.9) | 26 (86.7) |
| Presence of sub-RPE fluid, n (%) | 23 (59.0) | 16 (53.3) |
| CNV-associated lesion area, mm2, mean (SD) | 4.4 (4.1) | 4.9 (4.0) |
All randomised analysis set.
BCVA, best-corrected visual acuity; CNV, choroidal neovascularisation; CST, central subfield thickness; IRF, intraretinal fluid; PCV, polypoidal choroidal vasculopathy; RPE, retinal pigment epithelium; SRF, subretinal fluid.